



Project title: European Federation for Cancer Images

Project acronym: EUCAIM

Grant Agreement: 101100633

Call identifier: DIGITAL-2022-CLOUD-AI-02

D1.2: EUCAIM visual identity and online presence

Partner(s): EIBIR

Author(s): Peter Gordebeke

Date of delivery: 31/03/2023

Version: 1

Table of contents

Introduction	2
Visual identity	2
Branding guidelines	2
Logo usage	3
Colors.....	3
Typography	3
Color palette.....	4
PowerPoint template for presentations	4
Reusable assets for project introductions	6
EUCAIM online presence	6
Landing page	6
About Us page	7
What We Do page.....	7
Consortium and partner-specific pages.....	7
Achievements	7
Frequently Asked Questions.....	7
Contact page	7
Social media guidelines and templates.....	7
Hashtags.....	8
Institutional Accounts.....	8
Security and compliance	8
Cookie policy	8
Annex: screenshots.....	11

Introduction

The EUROpean Federation for CANcer IMages (EUCAIM) project is a crucial component of Europe's Beating Cancer Plan, aiming to create a federated infrastructure for cancer imaging and AI that will ultimately benefit patients, clinicians, and researchers alike. As a collaborative effort involving numerous partners, it is essential to maintain clear and consistent communication throughout the project's duration.

This document described the overall EUCAIM visual identity (similar to Deliverable D1.1) and the online presence.

Visual identity

Branding guidelines

The EUCAIM project's visual identity plays a crucial role in maintaining a consistent and professional image across all communication materials. To ensure that all project partners adhere to the same design principles, a set of branding guidelines has been developed. These guidelines cover various aspects of the project's visual identity, including logo usage, typography, color palette, and other design elements. By following the branding guidelines, partners can ensure that all EUCAIM-related materials are easily recognizable and convey a unified message.

Logo usage

The EUCAIM logo is an essential component of the project's visual identity. This section outlines the proper use of the logo, including placement, sizing, and any restrictions on altering its design. By adhering to these guidelines, partners can ensure that the logo is used consistently across all communication materials.

Colors

The EUCAIM logo is available in six colourways:

- Full colour
- Indigo Blue with coloured C
- White with coloured C
- Monochrome Indigo Blue
- Monochrome White
- Monochrome Black

The full colour logo is to be used whenever possible and legible.


The Indigo Blue with coloured C logo should be used on light coloured backgrounds where legibility of the full colour logo is not satisfactory.

The white with colour C logo is to be used on medium to dark coloured backgrounds.

The three monochrome coloured logos can be used if the colour palette must be limited, or for legibility reasons. The monochrome Indigo Blue and monochrome Black logos can be used on light backgrounds. The monochrome White logo can be used on dark background.



Whenever you use the logo, it should be surrounded with clear space to ensure its visibility and impact. No graphic elements of any kind should invade this zone.



The minimum whitespace surrounding the logo should be 50% of the logo's vertical height, at all sides.

The logo and the icon's exclusion zone is equal to half the height of the icon.

Typography

Typography plays a significant role in maintaining a consistent visual identity for the EUCAIM project. This section provides details on the typefaces, font sizes, and font styles that should be used in project materials, as well as any recommended usage for headings, subheadings, and body text.

The typeface used in the logo is based on Expressway. The EU is based on Expressway Light, whereas the AIM is based on Expressway Semibold. The C is a custom design.

For print applications, usage of the Expressway typeface is recommended.

For web use, usage of the Overpass typeface is recommended. Overpass Mono can be used, capitalized, as an alternative typeface for emphasis.

For offline, but digital use, in situations where neither Expressway or Overpass typefaces are available, the fall back typeface is Arial.

Font sizes should be selected for optimal legibility and not condensed.









Increased font weights should be used for emphasis, together with a colour emphasis.

Headings, subheading and body text can use the same typeface, or one of the recommended typefaces, which can be mixed and matched between headings and body text. The typefaces within one type of text should not be mixed, i.e., if headings are using a different typeface than the body, the heading should always use the same typeface and the body text should only use one typeface as well.

Color palette

The EUCAIM project's colour palette consists of a set of primary and secondary colors that have been carefully chosen to represent the project's values and goals. This section outlines the specific colour codes (RGB, HEX, HSL and CMYK) for each colour in the palette and provides guidelines on how to apply these colors to various communication materials.

In the table below eight colours are featured, as well as their usage.

Color	Indigo Blue	Dark Sky Teal	Keppel Teal	Macaroni Orange	Fulvous Orange	Carmine Red	Ochre Orange	Topaz Orange
Swatch								
RGB	38, 51, 107	117, 200, 206	52, 155, 162	253, 198, 137	230, 132, 0	234, 109, 112	217, 124, 21	255, 206, 128
HEX	26336B	75C8CE	349BA2	FDC689	E68400	EA6D70	D97C15	FFCE80
HSL	229, 48, 28	184, 43, 81	184, 68, 64	32, 46, 99	34, 100, 90	359, 53, 92	32, 82, 47	37, 100, 75
CMYK	98, 91, 29, 17	43, 3, 0, 19	68, 4, 0, 37	0, 22, 46, 1	0, 43, 100, 10	0, 53, 52, 8	12, 60, 100, 1	0, 20, 57, 0
Usage	Primary	Primary	Secondary	Tertiary	Primary	Secondary	Gradient	Gradient
Logo	x	x					x	x
Text	x	x	x		x	x		
Graphs	x	x	x	x	x	x		
Gradient		x	x				x	x

Indigo Blue is the primary colour for text. It is also featured in the logo.

Dark Sky Teal is also featured in the logo, and can be an alternative colour for text. However, it is recommended to use Keppel Teal as a secondary text colour for emphasis, when using Indigo Blue as a primary text colour.

Fulvous Orange is another primary colour that can be used for the text or as a secondary colour for emphasis. It is not used in the logo.

Carmine Red is a secondary colour that can be used for emphasis. Usage of Carmine Red in combination with one of the orange colours should be prevented within text. It can be used within graphs.

The orange gradient in the logo is based on a 0-100 gradient of Ochre Orange and Topaz Orange. These colours should not be used for text for contrast reasons.

PowerPoint template for presentations

To ensure consistency in presentations related to the EUCAIM project, a PowerPoint template has been developed for use by all project partners. This template includes pre-designed slide layouts, typography, and colour schemes that adhere to the project's branding guidelines. By using the PowerPoint template, partners can create professional and visually cohesive presentations that align with the EUCAIM project's visual identity.

It features two designs with nine layouts each. The primary layout uses a Dark Sky Teal gradient as its main design element.

A secondary layout uses Macaroni Orange gradients as its main design element. The gradient is different from the primary design, so the secondary layout can be used for emphasis or as a visual break.

The overall look of the PowerPoint template is similar to the European Commission’s visual style for the European Cancer Imaging Initiative. Embracing similar styles and following a similar visual language helps in creating recognisability. The project website, which will be presented later in this document, deviates from the use of gradients in favour of implementing a more accessible website and user experience in terms of web-standards and legibility.



Slide with a table EUCAIM

Co-funded by the European Union

Slide with a line chart EUCAIM

Chart Title

Category	Series 1	Series 2	Series 3
Category 1	4.5	2.5	2.0
Category 2	2.5	4.5	2.0
Category 3	3.0	1.8	3.0
Category 4	4.5	2.8	5.0

Co-funded by the European Union

EUCAIM

Section slide
Section subtitle

Co-funded by the European Union

EUCAIM

Concent slide with caption
Caption and legend

Chart Title

Category	Series 1	Series 2	Series 3
Category 1	4.5	2.5	2.0
Category 2	2.5	4.5	2.0
Category 3	3.5	1.8	3.0
Category 4	4.5	2.8	5.0

Co-funded by the European Union

The template is available to the consortium on its collaborate platform and document repository Teamwork.

Reusable assets for project introductions

In addition to templates, a set of pre-made assets has been created to serve as a starting point for project partners when introducing the EUCAIM project. These assets cover essential information about the project, such as its objectives, work packages, and overall structure. Partners can use and adapt these pre-made slides as needed, ensuring that presentations maintain a consistent message and visual style.

Assets that are available includes pre-made PowerPoint slides, social media posts and images, text for scientific and lay audiences summarising the project, summaries of the work packages and more.

Please refer to Deliverable D1.1 for more information.

EUCAIM online presence

The EUCAIM project website, cancerimage.eu, has been developed as the main public-facing online presence for the project, and the research infrastructure that will be deployed under the name of Cancer Image Europe.

Currently, it contains the most important information about the project and efforts were made to keep the information understandable for the general public.

The website is a constantly changing and evolving platform. The initial release provides basic functionality and information, but will change substantially over the course of the project. A login or redirect to the actual research infrastructure dashboard will be included as soon as it is available for instance.

This also means that the overall look of the website can change, and the order of pages and information will be tweaked and finetuned as well.

All separate pages are attached at the end of this document.

Landing page

The landing page features an attention grabbing hero element at the top of the page with a bold headline. This is followed by more details about the objectives of the project. Both sections link to more in-depth information about EUCAIM.

Following this is a short overview of the main expected outcomes and a link to frequently asked questions. This is complemented by a block to guide users to further details about the work plan of the project.

A section linking to the project's achievements *and* resources is included after this. This links to publications, public deliverables and reports and a section linking to released tools and resources.

Related to this is the newsroom section, which is simply a collection of news posts.

The website also includes some quotes from key players in this space: Roberto Viola (Director General of DG CNECT), Lorena Boix Alonso (Director for Digital Society, Trust & Cybersecurity – DG CNECT), Regina Beets-Tan (President of the European Society of Radiology), and Marco Marsella (Head of Unit – DG CNECT – eHealth, Well-Being and Ageing)

As a final section, an overview of the consortium is included. All consortium partners are included with their logo and a link to a page for more details for all consortium partners is added.

The menu at the top of the page remains at the top for easy navigation.

A footer at the bottom of the page includes information about the EC funding and the disclaimer regarding the public views of EUCAIM. It also includes direct contact details and quick links to each main section.

About Us page

The About Us page provides more details about the project, it's mission, vision and the Cancer Image Europe platform.

What We Do page

The What We Do page provides more details on the workplan of the EUCAIM project, such as the specific objectives, and the work package descriptions.

Consortium and partner-specific pages

This page provides a geographical overview of the consortium, showing its pan-European nature, as a list of partners. Every partner can be clicked on for navigation to more details about each partner. This includes a general description of the organisation, their role in the project and the staff involved.

This page also includes information about the multidisciplinary nature of the consortium, and its complementary expertise.

Achievements

The Achievements page features searchable and sortable tables for three categories of public results: scientific publications, public deliverables and reports and tools/resources. The respective tables will be populated with results as they become available.

Frequently Asked Questions

The Frequently Asked Questions page includes an overview of frequently asked questions and their respective answers. This will be updated as the project progresses and the Cancer Image Europe platform becomes available.

Contact page

The contact page does not include any contact forms, but only provides details for direct contact means; a dedicated email address and a phone number.

The decision not to include a contact form was made for GDPR compliance reasons.

Social media guidelines and templates

To facilitate effective communication and promote the EUCAIM project on social media, we have prepared a set of guidelines and templates for project partners. These guidelines aim to ensure a consistent message and tone across various social media platforms while leveraging the existing reach of partners' institutional accounts.

The social media guidelines outline best practices for partners when sharing EUCAIM-related content on their institutional accounts. These guidelines cover aspects such as tone, language, and the use of visuals, ensuring that all social media posts align with the project's overall communication strategy and visual identity.

Hashtags

The two main hashtags that should be included in all EUCAIM-related social media posts are **#EUCAIM** and **#euCancerImaging**. By using these hashtags, partners can contribute to the online conversation surrounding the project and increase its visibility.

Institutional Accounts

Partners are encouraged to use their institutional social media accounts to share updates about the EUCAIM project. This approach takes advantage of the established audiences and reach of these accounts, ensuring that the project's messages reach a wide audience without the need to build a new follower base from scratch.

Security and compliance

All connections to and from the website are SSL-encrypted and secure.

All data is stored in a data center in Belgium.

A GDPR-compliant cookie banner for consent and management is implemented.

The backend of the website is running on WordPress with Elementor. Elementor does **not** set HTTP cookies. Instead, Elementor works with LocalStorage and Session Storage. However, these are legally treated as (HTTP) cookies. Rather than HTTP cookies, data stored is an entry in the local storage and in the session storage of the browser. The collected data will most only be stored on the visitor's local browser for a limited period and will not be sent to Elementor, the website operator's server or any third party.

The LocalStorage and Session Storage data is classified as essential according to the current state of knowledge. In this case, local storage and session storage are responsible for ensuring that pop-ups, sitebars, etc. are not displayed again so that the visitor can use the website undisturbed. Whether these "cookies" are actually considered necessary is disputed.

Nevertheless, according to ePrivacy Directive 2002/58/EC, access to browser memory is only permitted if the visitor has consented (GDPR Article 6 (1) lit. a) or if the access is absolutely necessary in order to provide or operate the service.

In both cases, this means that European users of Elementor should provide their website visitors with detailed information on what data is stored locally in accordance with the GDPR.

Since we consider local and session storage to be essential in this case, opt-in consent from website visitors is technically not needed. However, to err in the safe side, we comply with the obligation to inform according to Article 13 of the GDPR. In addition to cookies, we refer to the data storage in our cookie notice.

In addition to the Elementor local storage, we also intend to use Matomo Cloud for tracking visitor statistics. This data is also stored in Belgium. Matomo is a fully GDPR-compliant alternative to Google's Analytics for website. At the time of submission of this deliverable, this has not been implemented however.

Cookies are only stored on the visitors computer if they consent in the cookie notice. Following this, an option to manage consent is permanently available at the bottom right of each page.

A contact form is not provided on this website, as the added value and ease of use of such a contact form is not high enough considering the implication in processing data in terms of GDPR compliance.

Cookie policy

Cookie Policy

This Cookie Policy was last updated on March 30, 2023 and applies to citizens and legal permanent residents of the European Economic Area and Switzerland.

1. Introduction

Our website, <https://cancerimage.eu> (hereinafter: "the website") uses cookies and other related technologies (for convenience all technologies are referred to as "cookies"). Cookies are also placed by

third parties we have engaged. In the document below we inform you about the use of cookies on our website.

2. What are cookies?

A cookie is a small simple file that is sent along with pages of this website and stored by your browser on the hard drive of your computer or another device. The information stored therein may be returned to our servers or to the servers of the relevant third parties during a subsequent visit.

3. What are scripts?

A script is a piece of program code that is used to make our website function properly and interactively. This code is executed on our server or on your device.

4. What is a web beacon?

A web beacon (or a pixel tag) is a small, invisible piece of text or image on a website that is used to monitor traffic on a website. In order to do this, various data about you is stored using web beacons.

5. Cookies

5.1 Technical or functional cookies

Some cookies ensure that certain parts of the website work properly and that your user preferences remain known. By placing functional cookies, we make it easier for you to visit our website. This way, you do not need to repeatedly enter the same information when visiting our website and, for example, the items remain in your shopping cart until you have paid. We may place these cookies without your consent.

5.2 Statistics cookies

We use statistics cookies to optimize the website experience for our users. With these statistics cookies we get insights in the usage of our website. We ask your permission to place statistics cookies.

5.3 Marketing/Tracking cookies

Marketing/Tracking cookies are cookies or any other form of local storage, used to create user profiles to display advertising or to track the user on this website or across several websites for similar marketing purposes.

6. Placed cookies

Elementor - Statistics (anonymous)

We use Elementor for content creation.

This data is not shared with third parties.

7. Consent

When you visit our website for the first time, we will show you a pop-up with an explanation about cookies. As soon as you click on "Save preferences", you consent to us using the categories of cookies and plug-ins you selected in the pop-up, as described in this Cookie Policy. You can disable the use of cookies via your browser, but please note that our website may no longer work properly.

7.1 Manage your consent settings

Functional (Always active)

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Statistics

The technical storage or access that is used exclusively for statistical purposes.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

8. Enabling/disabling and deleting cookies

You can use your internet browser to automatically or manually delete cookies. You can also specify that certain cookies may not be placed. Another option is to change the settings of your internet browser so that you receive a message each time a cookie is placed. For more information about these options, please refer to the instructions in the Help section of your browser.

Please note that our website may not work properly if all cookies are disabled. If you do delete the cookies in your browser, they will be placed again after your consent when you visit our websites again.

9. Your rights with respect to personal data

You have the following rights with respect to your personal data:

- You have the right to know why your personal data is needed, what will happen to it, and how long it will be retained for.
- Right of access: You have the right to access your personal data that is known to us.
- Right to rectification: you have the right to supplement, correct, have deleted or blocked your personal data whenever you wish.
- If you give us your consent to process your data, you have the right to revoke that consent and to have your personal data deleted.
- Right to transfer your data: you have the right to request all your personal data from the controller and transfer it in its entirety to another controller.
- Right to object: you may object to the processing of your data. We comply with this, unless there are justified grounds for processing.

To exercise these rights, please contact us. Please refer to the contact details at the bottom of this Cookie Policy. If you have a complaint about how we handle your data, we would like to hear from you, but you also have the right to submit a complaint to the supervisory authority (the Data Protection Authority).

10. Contact details

For questions and/or comments about our Cookie Policy and this statement, please contact us by using the following contact details:

EIBIR - European Institute for Biomedical Imaging Research

Am Gestade 1

1010 Vienna

Austria

Website: <https://cancerimage.eu>

Email: office@eibir.org

Phone number: +431533406420

This Cookie Policy was synchronized with cookiedatabase.org on March 30, 2023.

Annex: screenshots



Cancer Image Europe is pioneering a pan-European federated infrastructure for cancer images, fuelling AI innovations

Cancer Image Europe provides a robust, trustworthy platform for researchers, clinicians and innovators to harness their data to improve AI for the benefit of cancer diagnosis and treatment of AI for cancer diagnostics.

By providing the infrastructure for the development of federated AI, Cancer Image Europe facilitates collaboration and data sharing between researchers, clinicians and innovators to accelerate the development of AI for cancer diagnosis and treatment.

[LEARN MORE](#)



Accelerating Innovations In Cancer Diagnosis And Treatment

- Federated Research Infrastructure**
EUCAIM provides a secure, scalable and interoperable infrastructure for federated research across Europe, enabling researchers to collaborate and share data across institutions.
- Artificial Intelligence Innovations**
EUCAIM provides a platform for researchers to develop and test AI models for cancer diagnosis and treatment, accelerating the development of AI for cancer.
- Collaboration And Exchange**
EUCAIM provides a platform for researchers, clinicians and innovators to collaborate and exchange knowledge, accelerating the development of AI for cancer.
- Improved Outcomes For Cancer Patients**
EUCAIM provides a platform for researchers, clinicians and innovators to develop and test AI models for cancer diagnosis and treatment, accelerating the development of AI for cancer.

[LEARN MORE](#)

The Cancer Image Europe Platform Is Unique Because It Will Foster The Transition From Research Into Clinical Practice

The EUCAIM platform is unique because it will foster the transition from research into clinical practice. It provides a secure, scalable and interoperable infrastructure for federated research across Europe, enabling researchers to collaborate and share data across institutions. This infrastructure will be used to develop and test AI models for cancer diagnosis and treatment, accelerating the development of AI for cancer.

[LEARN MORE](#)

Project Achievements And Resources

EUCAIM has achieved several milestones, including the development of a secure, scalable and interoperable infrastructure for federated research across Europe, enabling researchers to collaborate and share data across institutions.



Newsroom

- EUCAIM kick-off meeting in Brussels**
The EUCAIM kick-off meeting took place in Brussels on 14th October 2022. The meeting was attended by representatives from all participating institutions and was a great success.
- Cancer Image Europe KICK-OFF MEETING**
The EUCAIM kick-off meeting took place in Brussels on 14th October 2022. The meeting was attended by representatives from all participating institutions and was a great success.
- EUCAIM at ECR 2023**
EUCAIM will be present at the European Cancer Research Congress (ECRC) 2023 in Amsterdam, The Netherlands, from 15th to 19th September 2023.

[LEARN MORE](#)

Testimonials

"EUCAIM is a unique and innovative platform that provides a secure, scalable and interoperable infrastructure for federated research across Europe, enabling researchers to collaborate and share data across institutions. This infrastructure will be used to develop and test AI models for cancer diagnosis and treatment, accelerating the development of AI for cancer."



[LEARN MORE](#)

The EUCAIM Consortium

The EUCAIM Consortium is a pan-European collaboration of researchers, clinicians and innovators who are working together to develop and test AI models for cancer diagnosis and treatment, accelerating the development of AI for cancer.

[LEARN MORE](#)

[Front page](#)

Navigating The Future: Our Vision And And Mission

Our Mission

Our mission is to build a pan-European digital federated infrastructure of cancer-related images, which will be used for the development of AI tools toward Precision Medicine.

We hope that this infrastructure will provide the means to develop AI tools that will be able to enhance the (cancer) diagnosis procedure, treatment and the identification of the need for predictive medicine benefiting patients across Europe.

Our Vision For The Future

By building a pan-European digital federated infrastructure of cancer-related images, we will provide the means to the validation and development of AI tools, which will support and enhance the (cancer) diagnosis procedure, treatment and the identification of the need for predictive medicine. Overall, this infrastructure will provide a platform for developing AI tools that aim to enhance cancer treatment and the diagnosis procedure for patients.

We will also define the legal grounds for the operation of the federated data repository on the European scale by adapting to the particularities of the data management regulations of the different European countries.

Manage content

Our History

The EUCAIM project was born out of a need to overcome the lack of cancer diagnosis and treatment through the use of AI and medical imaging data that is available, but fragmented across Europe and the world.

To address this challenge, pan-European groups together and previously unmet needs of the patient community that through imaging, AI and predictive medicine, could help with disease prevention, early diagnosis and better treatment. By joining the research, healthcare providers, data and software developers, and various academic key players, the EUCAIM project is uniquely positioned to create and deploy a strong and ethical ecosystem of solutions that will catalyze the development and implementation of AI driven cancer diagnosis and treatment solutions, ultimately improving patient outcomes across Europe.

About The Project

This work is funded by the European Union under the Horizon Europe Programme, Grant Agreement No. 101019171. The project aims to develop and deploy AI tools for cancer diagnosis and treatment, based on federated learning, deep learning, and other machine learning techniques.

ANSWERS TO FREQUENTLY ASKED QUESTIONS

Driven By Our Goals And Values



Experience

Building on the experiences of the AI4Cancer project and the AI4Cancer project, we have gathered a large number of experts in the field of cancer imaging.



Real-World Data

Real-world data is essential for AI tools to be used in real-world settings and to ensure cancer image reproducibility.



Additional Providers

We will connect various clinical data providers from 15 countries to ensure data interoperability and Open Call for new data providers.



All Cancer Types

Cancer image federated learning and federated learning are key technologies for AI tools to be used in real-world settings.



Big Data

Cancer image federated learning and federated learning are key technologies for AI tools to be used in real-world settings.



Artificial Intelligence

At least 50 AI algorithms, tools and protocols need to be developed and implemented for AI tools to be used in real-world settings.

Summary

European Federation For Cancer Imaging (EUCAIM) is the cornerstone of the European Commission funded European Cancer Imaging Initiative, a flagship of Europe's leading Cancer Research Program, which aims to foster innovation of digital technologies in cancer treatment and care to achieve more precise and faster diagnosis and better care for cancer patients.

Health data, including medical images, are highly distributed and fragmented in Europe. Artificial Intelligence (AI) offers a paradigm shift towards early cancer detection, diagnosis, prognosis, and personalized medicine. In medical imaging, an increasing number of studies are reporting on what AI tools are making important contributions towards more precise diagnosis and better care for cancer patients. However, there are no large-scale federated learning initiatives in Europe to pool the available data and improve AI tools. The aim of the project is to address this issue by creating a federated learning infrastructure in Europe.

This research infrastructure will support the development and validation of AI tools toward Precision Medicine. Such AI tools will support and enhance the current diagnosis, prognosis, and treatment of the need for predictive medicine. Overall, this initiative will provide a platform to develop AI tools that aim to enhance cancer treatment and the diagnosis procedure for patients.

EUCAIM will be an open and accessible platform for federated learning of cancer image data through the projects of the Health Initiative. Furthermore, we will also create a platform for the development and deployment of the federated learning tools for AI tools to be used in real-world settings. The EUCAIM project will consist of the following tasks: (1) data governance and (2) AI tools development. The EUCAIM project will consist of the following tasks: (1) data governance and (2) AI tools development. The EUCAIM project will consist of the following tasks: (1) data governance and (2) AI tools development.

About Us Page



Uniting Europe's Cancer Data: Powering AI-Driven Medicine

The EUCAIM project aims to harness the efforts of pan-European digital research infrastructure of high-calibre researchers to create the next generation of cancer imaging AI. The project will be a multi-disciplinary effort, bringing together researchers from across Europe, for the development and validation of AI tools to assist in the diagnosis of cancer. The project will also focus on the development of cancer imaging AI tools to assist in the diagnosis of cancer. The project will also focus on the development of cancer imaging AI tools to assist in the diagnosis of cancer.

Cancer Image Europe Will

- Improve Detection And Diagnosis**
Develop and validate AI tools to assist in the diagnosis of cancer. The project will also focus on the development of cancer imaging AI tools to assist in the diagnosis of cancer.
- Accelerate AI Development**
Develop and validate AI tools to assist in the diagnosis of cancer. The project will also focus on the development of cancer imaging AI tools to assist in the diagnosis of cancer.
- Showcase Trustworthiness**
Develop and validate AI tools to assist in the diagnosis of cancer. The project will also focus on the development of cancer imaging AI tools to assist in the diagnosis of cancer.



Work Package Synergy

The EUCAIM project is a complex one, involving a wide range of stakeholders and disciplines. The project will be a multi-disciplinary effort, bringing together researchers from across Europe, for the development and validation of AI tools to assist in the diagnosis of cancer.

- Project Management And Coordination**
 - Work Package 1**
The primary objective of WP1 is to establish the most effective governance, contractual, administrative, and financial management structure by providing different options and models for the project. This work package focuses on the coordination of project activities and ensures quality and timeliness of project progress and results, while addressing risk planning and management. WP1 will also carry out the communication and dissemination activities of the EUCAIM.
- Engagement And Liaison Of Data Providers**
 - Work Package 2**
WP2 is designed to establish the collaborative and trust environment of the project both data providers, but it is possible to collect, available, distributed in the project. The main aim is to develop an iterative approach to facilitate the participation and involvement. This action plan will be used to build trust, and support activities as well as to plan activities.
- Ethical And Legal Aspects**
 - Work Package 3**
WP3 is designed to establish the ethical and legal aspects of the project. This work package focuses on the coordination of project activities and ensures quality and timeliness of project progress and results, while addressing risk planning and management. WP3 will also carry out the communication and dissemination activities of the EUCAIM.
- Governance And Implementation Of The Central Hub**
 - Work Package 4**
WP4 is designed to establish the governance and implementation of the central hub. This work package focuses on the coordination of project activities and ensures quality and timeliness of project progress and results, while addressing risk planning and management. WP4 will also carry out the communication and dissemination activities of the EUCAIM.
- Data Federation And Interoperability Framework**
 - Work Package 5**
WP5 is designed to establish the data federation and interoperability framework. This work package focuses on the coordination of project activities and ensures quality and timeliness of project progress and results, while addressing risk planning and management. WP5 will also carry out the communication and dissemination activities of the EUCAIM.
- Federated Data Processing And Analysis**
 - Work Package 6**
WP6 is designed to establish the federated data processing and analysis framework. This work package focuses on the coordination of project activities and ensures quality and timeliness of project progress and results, while addressing risk planning and management. WP6 will also carry out the communication and dissemination activities of the EUCAIM.
- Use Cases For Platform Expansion And Validation**
 - Work Package 7**
WP7 is designed to establish the use cases for platform expansion and validation. This work package focuses on the coordination of project activities and ensures quality and timeliness of project progress and results, while addressing risk planning and management. WP7 will also carry out the communication and dissemination activities of the EUCAIM.
- Business & Sustainability Models**
 - Work Package 9**
WP9 is designed to establish the business and sustainability models. This work package focuses on the coordination of project activities and ensures quality and timeliness of project progress and results, while addressing risk planning and management. WP9 will also carry out the communication and dissemination activities of the EUCAIM.

Co-funded by the European Union

Quick Links

- Home
- About Us
- Partners
- Accompany
- News
- Contact Us
- Privacy Policy
- Cookie Policy

Get In Touch

central@eucaim.eu

+49 930 906 404 323

Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission.

What We Do Page

Project Achievements And Resources

Take A Look At Our Latest Achievements And Resources

Discover the most recent accomplishments and resources from the EUCAIM project as we continue to push the boundaries of cancer diagnostics and treatment.

Dive into our latest scientific publications, where our team of experts share cutting-edge research and findings that are shaping the future of cancer care.

Browse through our comprehensive public deliverables and reports to stay up-to-date with the project's progress and learn about the milestones we've achieved.

Finally, take advantage of our innovative online tools, developed to provide researchers, clinicians, and innovators with access to invaluable data and insights, ultimately driving transformative advancements in cancer diagnostics and treatment.

Join us on our journey towards revolutionizing cancer care through the power of AI and medical imaging.

Scientific Publications

Search:

Title	Author(s)	Journal	Date	DOI
N/A	N/A	N/A	N/A	N/A

Showing 1 to 1 of 1 entries

Manage consent

Public Deliverables And Reports

Search:

Title	Author(s)	Date	Download
N/A	N/A	N/A	N/A

Showing 1 to 1 of 1 entries

Tools And Resources

Search:

Name	Description	Date	Download
N/A	N/A	N/A	N/A

Showing 1 to 1 of 1 entries

March 30, 2023

EUCAIM Kick-Off Meeting In Brussels

Radiology leads flagship of Europe's Beating Cancer Plan – Kick-off for federated European infrastructure for cancer images

The EUCAIM consortium and the European Commission are excited to announce the official launch of the European Federation for Cancer Images (EUCAIM), a ground-breaking federated infrastructure deployment project aiming to power up imaging and AI towards precision medicine for Europe's cancer patients and citizens.

EUCAIM will address the fragmentation of existing cancer image repositories and establish a distributed Atlas of Cancer Imaging with over 60 million anonymised cancer image data from over 100,000 patients, accessible to clinicians, researchers and innovators across the EU for the development and benchmarking of trustworthy AI tools.

The infrastructure will be further populated by observational studies from hospitals (21 clinical sites in 12 EU countries), include clinical images and link with pathology, molecular and laboratory data and will be expanded to at least 30 distributed data providers from 15 countries by the end of the 4-year project. Federated AI solutions will be trained at the hospital data warehouses, keeping data privacy.

EUCAIM is the cornerstone of the European Commission initiated [European Cancer Imaging Initiative](#), a flagship of Europe's Beating Cancer Plan (EBCP), which aims to foster innovation and deployment of digital technologies in cancer treatment and care, to achieve more precise and faster clinical decision-making, diagnostics, treatments and predictive medicine for cancer patients.

It is scientifically led by Prof. Luis Martí-Bonmatí, Director of the Medical Imaging Department, Chairman of Radiology, La Fe University and Polytechnic Hospital (Valencia, ES) and coordinated by the [European Institute for Biomedical Imaging Research \(EIBIR\)](#), established by and headquartered at the European Society of Radiology in Vienna, AT.

The project builds upon the results of the work of the "AI for Health Imaging" (AI4HI) Network which consists of 5 large EU-funded projects on big data and AI in cancer imaging: Chameleon, EuCanImage, ProCancer-I, Incisive and Primage.

EUCAIM brings together 76 partners from 14 EU member states, covering competences in cancer imaging and care, big data in medical imaging, FAIR data management, ethical and legal aspects of medical data, development and deployment of research infrastructures, AI and machine learning, as well as dissemination, communication and stakeholder outreach in biomedical imaging.

In line with the European data strategy and supporting the goals of the European Health Data Space, the EUCAIM will partner with the AI Testing and Experimentation Facility for Health under the Digital Europe Programme, allowing SMEs to access its infrastructure, and rollout will be supported by the services of the European Digital Innovation Hubs.

EUCAIM follows an inclusive, collaborative approach and will interact with a plethora of stakeholders to ensure uptake at political level in member states and wide use of the infrastructure by clinicians, researchers and innovators. Clinical data providers will be invited to join the initiative through an open call procedure during the course of the project.

More information on EUCAIM at <https://www.eibir.org/projects/eucaim/>

European Commission Factsheet European Cancer Imaging Initiative and EUCAIM:
<https://ec.europa.eu/newsroom/dae/redirection/document/92245>

European Commission Press Release on launch event of European Cancer Imaging Initiative, 23 January 2022: https://ec.europa.eu/commission/presscorner/detail/en/ip_23_286

Contact for enquiries

Mr Peter Gordebeke, pgordebeke@eibir.org, European Institute for Biomedical Imaging Research (EIBIR)
Source: <https://www.eibir.org/projects/eucaim/pressreleases/radiology-leads-flagship-of-europes-beating-cancer-plan-kick-off-for-federated-european-infrastructure-for-cancer-images/>

[Manage consent](#)

[PREVIOUS ARTICLE](#)

Contact Us

PROJECT COORDINATORS

Peter Gordebeke and Monika Hierath
 European Institute for Biomedical Imaging Research (EIBIR)
 Am Gestade 1
 1010 Vienna
 Austria

SCIENTIFIC COORDINATOR

Prof. Luis Martí-Bonmatí
 Biomedical Imaging Research Group
 Medical Imaging Department
 La Fe University Hospital Valencia
 Avda. Fernando Abril Martorell, 106 – Torre E
 46026 Valencia
 Spain

SEND US A MESSAGE

Quick Links

[Home](#)
[About us](#)
[What we do](#)
[FAQ](#)
[Achievements](#)
[Partners](#)
[Contact us](#)
[Sitemap](#)
[Cookie Policy](#)

Get In Touch

contact@cancerimage.eu

+43-1-533-4064-323



Manage consent

Frequently Asked Questions

- 1. Where is patient data and which countries are currently involved in EUCAIM?
- 2. In which countries are the data being collected?
- 3. How will the quality of data be checked and verified? What steps are taken to ensure that the data is of high quality?
- 4. How is the data being collected and stored?
- 5. How is the data being collected and stored?
- 6. How is the data being collected and stored?
- 7. How is the data being collected and stored?
- 8. How is the data being collected and stored?
- 9. How is the data being collected and stored?
- 10. How is the data being collected and stored?

Which EU Member States and Which Clinical Sites are Currently Involved in EUCAIM?

The EUCAIM study involves clinical sites and clinical sites involved in EUCAIM projects with an overview of the infrastructure to be developed to ensure that the data is of high quality and that the data is collected in a secure and transparent manner.

How Will The Quality Of Data Be Controlled And Ensured? We Know That Anticipations Vary From One Institution To Another, Will You Have Mechanisms To Foster Data Quality?

The EUCAIM project will ensure that the data is of high quality and that the data is collected in a secure and transparent manner. This will be achieved through a combination of measures, including the use of standardised data collection tools, the implementation of quality control procedures, and the use of data quality metrics to monitor the quality of the data throughout the project.

How Will EUCAIM Manage The Legal Requirements Of The General Data Protection Regulation (GDPR) When Collecting The Data? In Practical Terms Will Data Leave The Hospital? How Will You Ensure Data Privacy?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

Data Leave The Hospital? How Will You Ensure Data Privacy?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

Countries From Central/Eastern Europe Seem To Be Less Represented In The EUCAIM Consortium, Will There Be Opportunities For Countries Not Represented Yet To Join The Consortium? When?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

Will There Be Any Emphasis On Childhood Cancers And Involving Adolescents And Young Adults With Cancer In Research?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

How Does The European Cancer Imaging Initiative Ensure That There Is Or Will Be An Active Participation Of The Patient Either As A Stakeholder Or A Partner? How Will Patient Representatives/Organisations Be Involved In The EUCAIM Project?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

Will You Engage With Standardisation Organisations To Improve And Adapt Existing Standards With Project Knowledge?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

Is The European Cancer Imaging Initiative Limited To AI Or Do You Accept Also Other Imaging Technologies As Hardware, Software And Firmware For Time-Of-Flight PET For Early Cancer Detection And Low-Dose Usage Of FDG?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

Will Cardio Oncology Imaging Of The Heart Be Included In The Cancer Imaging And AI Initiative? Cardiology And Heart Failure Is One Of The Potential Side Effects Of Chemotherapy Treatment Of Cancers.

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

Will The Federated Infrastructure Include Historical Images?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

What Is The Role Of Proprietary Data In The Infrastructure Created By EUCAIM Project?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

Will Clinical Trial Data From Industry Sponsored Studies Be Included In The Infrastructure? Are These Data Contributions From Clinical Sites Already Secured?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

How Will The Testing And Experimentation Facility For Health (HEALTH) And EUCAIM Be Connected To The Infrastructure?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

How Will You Address The Risk Of Participating Institutions Becoming More Reluctant To Share And Annotate Data As The Time Goes By/When The EU Funding For The EUCAIM Project Is Over? Do You Have A Policy In Place To Counter This Risk?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

For The Sustainability And Impact Of The New Services And Infrastructure, It Will Be Of Interest To Develop Training Solutions Tailored To The New Services (Targeting Health Care Professionals As End Users). How Do You Envision The Engagement Of Academics (Universities, Policy Makers) In This Step?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.


Is There A Plan To Develop A Standard Content Of Data To Be Made Available To Researchers? In Particular, Is Data On Radiation Exposure To Be Included E.G. To Allow Developments Around Meeting EU Legal Requirements (European Directive) For Radiation Protection Of Patients?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

How Can A Start-Up With A Proven Technology To Early Detect Cancer Be Part Of This Initiative?

The EUCAIM project will ensure that the data is collected in a secure and transparent manner, and that the data is protected in accordance with the requirements of the GDPR. This will be achieved through a combination of measures, including the use of secure data storage, the implementation of data access controls, and the use of data anonymisation techniques to protect the identity of the patients.

FAQ Page



Our Consortium

Meet Our Collaborative Network: The Experts Behind EUCAIM

The EUCAIM consortium consists of 25 partners from 14 countries. Many partners are part of the EU Horizon Health Research Program, including a large number of institutions from Italy, Sweden, Belgium, France, Germany, Austria, Spain, Portugal, Cyprus, The Netherlands, Czechia, Finland, Greece, Poland, and the UK. The consortium also includes other European Research Infrastructure, such as EMBL, Helmholtz, and the European Research Infrastructure Consortium (ERIC). The consortium also includes other European Research Infrastructure, such as EMBL, Helmholtz, and the European Research Infrastructure Consortium (ERIC). The consortium also includes other European Research Infrastructure, such as EMBL, Helmholtz, and the European Research Infrastructure Consortium (ERIC).



Austria

- Institute for Bioinformatics
- Institute for Bioinformatics and Health Research
- Institute for Bioinformatics and Health Research
- Institute for Bioinformatics and Health Research

Belgium

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

Cyprus

- European Commission

Czechia

- Institute for Agricultural and Fisheries Research

Finland

- Institute for Agricultural and Fisheries Research

France

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

Germany

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

Greece

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

Italy

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

The Netherlands

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

Poland

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

Portugal

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

Spain

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

Sweden

- Institute for Agricultural and Fisheries Research
- Institute for Agricultural and Fisheries Research

EUCAIM is a consortium of 25 partners from 14 countries. Many partners are part of the EU Horizon Health Research Program, including a large number of institutions from Italy, Sweden, Belgium, France, Germany, Austria, Spain, Portugal, Cyprus, The Netherlands, Czechia, Finland, Greece, Poland, and the UK.

Quick Links

- Home
- About EUCAIM
- Our vision
- Our partners
- Our projects
- Contact
- Privacy Policy
- Terms & Conditions

Get In Touch

EUCAIM@ec.europa.eu

+352 66 17 99 81 26



EUCAIM is funded by the European Union as part of the Horizon Health Research Program. The consortium is supported by the European Research Infrastructure Consortium (ERIC) and the European Research Infrastructure Consortium (ERIC). The consortium is supported by the European Research Infrastructure Consortium (ERIC) and the European Research Infrastructure Consortium (ERIC). The consortium is supported by the European Research Infrastructure Consortium (ERIC) and the European Research Infrastructure Consortium (ERIC).

Consortium Overview

University Hospital Aachen

UNIKLINIK RWTHAACHEN

The Universitätsklinikum Aachen ("University Hospital Aachen", UKA) is a German university hospital, affiliated with the RWTH Aachen University and known for its advanced medical research and innovative treatments. It is one of Europe's largest hospital buildings, housing 32 clinics and institutes covering a wide range of medical specialties such as cardiology, neurology, oncology, and transplantation. Since its establishment in 1870, UKA has grown into one of the largest and most respected medical centers in Germany and across the borders of neighbor countries, employing over 8,000 staff members and treating more than 300,000 patients each year. In addition to its clinical activities, UKA is also known for its groundbreaking research in the fields of medicine, biology, and engineering. Its scientists and physicians collaborate closely with other academic institutions and industry partners to develop new therapies and technologies.

The Clinic for Operative Intensive Medicine and Intermediate Care (OIM) is one of the largest clinics within the University Hospital Aachen. The clinic consists of seven wards with ~130 patient beds providing interdisciplinary care in more than seven key medical areas ranging from severe trauma to weaning. In addition to the patient care activities, the OIM is also highly active in research and development, producing over 150 publications per year in high-impact journals. It also houses the Telemedicine Center (TMZ), which provides more than 1000 remote consultations to regional hospitals per year, allowing the regional hospitals to access medical specialists. Furthermore, TMZ is a pioneer in the field of eHealth research and developed THALEA, which is a remote multi-ICU monitoring platform with international partners as a part of the EU Horizon 2020 Programme. Working closely with TMZ, under OIM is the Innovation Center for Digital Medicine (IZDM). IZDM is the pacemaker and initiator for the further development of digital medicine and the improvement of intersectoral patient care in Germany and Europe. The center focuses on the research and development of a variety of topics from clinical robotics, clinical decision support systems, to digital skills education for healthcare transformation.

Role of institution in the project

UKA is involved in WPs 6 and 7. In T6.3 UKA will participate in the definition and implementation of privacy-preserving components by contributing its perspectives in both German national and international experiences in dealing with patient data protection. In T7.1a UKA will help disseminate the external open call for new use cases. In T7.1b UKA will give input on potential use cases that require the perspective of Intensive Care Medicine. In T7.2 UKA will contribute ICU Data. In T7.3 UKA will provide ICU perspectives on data and tools. In T7.4 UKA will provide ICU perspectives of the platform.



Univ.-Prof. Dr. Med. Gernot Marx

Univ.-Prof. Dr. med. Gernot Marx, FRCA is the Director of the Clinic for Operative Intensive Medicine and Intermediate Care (OIM) at the University Hospital Aachen. He is also a board member of both the German Society of Anesthesia (DGAI) and Intensive Care and German Interdisciplinary Association of Critical Care and Emergency Medicine (DIVI), as well as the Chairman of the Innovation Center for Digital Medicine in Aachen (www.izdm.de). Prof. Marx is an expert in the field of telemedicine and eHealth. He is the editor of four ICU books and on the editorial board of five ICU journals. He has extensive experience coordinating close collaborations between academic/clinical researchers and industry partners in interdisciplinary projects at the regional, national, and international levels. Most notably, in recent national projects under the German Medical Informatics Initiative, he was the head of the Use Case ASIC and DigitalHub DISTANCE projects under the SMITH Consortium that was instrumental in the creation of the Data Integration Center in Aachen to promote the national interoperability of health data. Furthermore, his team was a key contributor in the EU Horizon 2020 project, Smart4Health, which developed an online platform to collect, manage, share, and donate health-related data throughout the EU.

Manage consent

Dr. Joyce Kao

Dr. Joyce Kao is a Senior Project Manager of EU Projects at the Innovation Center for Digital Medicine under the Operative and Intensive Medicine Department at the University Hospital RWTH Aachen (<https://www.izdm.de>). She obtained her Ph.D. in Computational Biology and Bioinformatics from the University of Southern California and held postdoctoral positions at New York University and ETH Zürich with a focus on population genomics and the development of bioimaging and analysis pipelines for high-throughput phenotyping. She is a co-founder of the Open Innovation in Life Sciences (<https://www.openinnovationinlifesciences.com>), a non-profit association in Switzerland that promotes Open Science among early career researchers and trains Open Science Ambassadors as a mentor and expert for the UK-based non-profit organization, Open Life Science (<https://openlifesci.org>). Her professional passions are creating open working environments using digital tools that promote efficient collaborative problem-solving.



Andreas Bleilevens

Andreas Bleilevens is a Project Manager at the Innovation Center for Digital Medicine within the Clinic for Operative Intensive Medicine and Intermediate Care at the University Hospital Aachen. Since 2014 working at the University Hospital Aachen, he gathered a lot of experience managing laboratories and research projects. He is a Master of Science in the field of Laboratory Animal Science. He has more than 8 Years of experience in the field of Cancer research. In addition, he specialized during his masters in the field of microsurgery and imaging. The urgently needed digitization of the health system and better communication between the different entities are his professional focus.

Antonios Antonopoulos

Antonios Antonopoulos is a research associate for the data evaluation department at the Innovation Center for Digital Medicine within the Clinic for Operative Intensive Medicine and Intermediate Care at the University Hospital Aachen. Originally a physicist, he completed the MSc Physics program of RWTH Aachen in 2018 with a focus on nanophotonics and phase-change materials. Since 2019 he has switched focus into the field of data analysis, working in varied fields such as biophysics, near-infrared optics and lately healthcare. He specializes in utilizing various data analysis tools in support of the team's data evaluation requirements.



Manage Cookie Consent ✕

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

[Accept](#) [Deny](#) [View preferences](#)

[Cookie Policy](#)

GDPR-compliant EU Cookie Notification